ADA 2018: CV Benefits of SGLT-2 Inhibitors

Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
© 2023 MJH Life Sciences

All rights reserved.